Adjunct Professor @ Department of Neuroscience, Icahn School of Medicine at Mount Sinai
Honorary Visiting Professor, School of Physiology, Pharmacology, and Neuroscience @ University of Bristol
Vice President, CSO, Neuroscience Site Leader, New York @ Eli Lilly and Company
Executive Director, Neuroscience CSO and Lilly Neuroscience Site Leader, New York @ Eli Lilly and Company
Executive Director and CSO, Psychiatric Disorders Research @ Eli Lilly and Company
Executive Director and CSO, Pain and Migraine Reserach and Psychiatric Disorders Research @ Eli Lilly and Company
CSO Pain and Migraine Research @ Eli Lilly and Company
Director, Neuroscience Division @ Eli Lilly and Company
David Bleakman's Education
The University of Chicago
Post-doctoral Fellow
1989 - 1993
King's College London
Doctor of Philosophy - PhD (Physiology, General)
David Bleakman's Skills
Clinical Development
Clinical Trials
Biochemistry
Oncology
Biomarkers
Biotechnology
CRO
Drug Development
Drug Discovery
In Vitro
David Bleakman's Summary
David Bleakman, based in New York, New York, United States, is currently a President Drug Discovery and Development at PsychoGenics, bringing experience from previous roles at Redpin Therapeutics Inc., Department of Neuroscience, Icahn School of Medicine at Mount Sinai, University of Bristol and Eli Lilly and Company. David Bleakman holds a 1989 - 1993 Post-doctoral Fellow @ The University of Chicago. With a robust skill set that includes Clinical Development, Clinical Trials, Biochemistry, Oncology, Biomarkers and more, David Bleakman contributes valuable insights to the industry. David Bleakman has 3 emails on RocketReach.